Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 89.7%

Neg 89.7% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Alvotech (NASDAQ:ALVO) with a Underweight and lowers the price target from $5 to $4.